Last reviewed · How we verify
Oral chemotherapy
This oral chemotherapy drug works by interfering with DNA replication and cell division.
This oral chemotherapy drug works by interfering with DNA replication and cell division. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer.
At a glance
| Generic name | Oral chemotherapy |
|---|---|
| Also known as | OC, Gemcitabine/Cisplatin |
| Sponsor | All India Institute of Medical Sciences |
| Drug class | Chemotherapeutic agent |
| Target | Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It does this by targeting rapidly dividing cancer cells, which are more susceptible to the drug's effects. This leads to cell death and ultimately, tumor shrinkage.
Approved indications
- Metastatic breast cancer
- Metastatic non-small cell lung cancer
Common side effects
- Nausea
- Vomiting
- Hair loss
- Fatigue
- Anemia
Key clinical trials
- Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors (PHASE1)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Substance Misuse To Psychosis for Stimulants (PHASE2, PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral chemotherapy CI brief — competitive landscape report
- Oral chemotherapy updates RSS · CI watch RSS
- All India Institute of Medical Sciences portfolio CI